Article Text

PDF
Anti-tumour necrosis factor α therapy in patients with impaired renal function
  1. Axel J Hueber1,
  2. Andac Tunc1,
  3. Georg Schett1,
  4. Bernhard Manger1
  1. Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen–Nuremberg, Erlangen, Germany
  1. Correspondence to:
    Dr A J Hueber
    Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen–Nuremberg, Krankenhausstr 12, 91054 Erlangen, Germany; axel_hueber{at}web.de

Statistics from Altmetric.com

Renal insufficiency is a common comorbidity in patients with inflammatory rheumatic diseases such as rheumatoid arthritis and psoriatic arthritis. Decreased renal function is a limiting factor for the use of non-steroidal anti-inflammatory drugs and disease-modifying antirheumatic drugs. Therefore, the availability of therapeutic alternatives would improve our treatment options for these patients. For tumour necrosis factor α (TNFα) inhibitors, no data about their use in patients with impaired renal function are available, because it has been an exclusion criterion in all major clinical trials.

We therefore retrospectively analysed all patients from our institution who had increased serum creatinine levels before or during treatment with TNFα antagonists. All patients with a serum creatinine ⩾1.1 mg/dl and treatment with infliximab, etanercept or adalimumab were included. We were able to identify nine patients with rheumatoid arthritis, one patient with …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.